CDK8 and cancer: On the other hand, potential target cancers could be identified through informatic analysis of clinical data, which may reveal tumor types where CDK8/19 or their binding partner Cyclin C (CCNC) would be amplified or overexpressed or where CDK8/19 expression would be associated with bad prognosis.